Critical Contrast: Viewray (VRAY) vs. Vaso (VASO)

Viewray (NASDAQ:VRAY) and Vaso (OTCMKTS:VASO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Earnings & Valuation

This table compares Viewray and Vaso’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Viewray $34.04 million 19.63 -$72.17 million ($1.04) -6.71
Vaso $72.78 million 0.08 -$4.53 million N/A N/A

Vaso has higher revenue and earnings than Viewray.

Risk and Volatility

Viewray has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Vaso has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Viewray and Vaso, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viewray 0 0 6 0 3.00
Vaso 0 0 0 0 N/A

Viewray presently has a consensus price target of $13.25, indicating a potential upside of 89.83%. Given Viewray’s higher probable upside, equities research analysts plainly believe Viewray is more favorable than Vaso.

Profitability

This table compares Viewray and Vaso’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Viewray -105.09% -105.63% -38.20%
Vaso -4.65% -46.63% -6.69%

Insider and Institutional Ownership

98.3% of Viewray shares are owned by institutional investors. 43.9% of Viewray shares are owned by company insiders. Comparatively, 9.1% of Vaso shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Viewray beats Vaso on 6 of the 11 factors compared between the two stocks.

About Viewray

ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.

About Vaso

Vaso Corporation operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging capital equipment, GEHC service agreements, and GEHC and third party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices. This segment provides Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for physiological signals, such as ECG and blood pressure; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsaion therapy systems that are used for non-invasive, outpatient treatment of ischemic heart disease, as well as in-service and training support. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was founded in 1987 and is headquartered in Plainview, New York.

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit